sacituzumab
gilead sciences
['impact,(-impacte),(-impacti),(-impactf)', ' sg ', 'sacituzumab', 'sacitu, govi', 'tropics-02']
tropics-02: sacituzumab govitecan vs tpc, 3.2 month in os with sg (hr 0.79; 95% ci 0.65-0.96), p=0.02. 20% of bcs are trop-2 neg. trop-2 expression wasn t assessed ?what s the impact on these data of treating trop-2 neg bcs. pd was best response in 20% of sg group #esmo2022 
Professor of Translational Oncology and Consultant Medical Oncologist